Gut bacteria booster may stop transplant complication

NCT ID NCT04373057

Recruiting now Prevention Sponsor: University of Kansas Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a dietary supplement called galacto-oligosaccharide (GOS) can prevent acute graft-versus-host disease (GVHD) in people receiving a stem cell transplant. GVHD is a serious complication where donor cells attack the patient's body. The supplement aims to change gut bacteria to reduce this risk. The trial involves 128 adults aged 18-80 and has two phases: first finding the best dose, then comparing GOS to a placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE GVHD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute graft versus host disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE GVHD

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Duke
ACTIVE_NOT_RECRUITING

Durham, North Carolina, 27710, United States
Kansas University Medical Center
RECRUITING

Kansas City, Kansas, 66160, United States

Contact